EU

Dogs Thrive on Vegan Diets, Demonstrates the Most Comprehensive Study So Far

Retrieved on: 
tisdag, april 23, 2024
Urine, Dicarboxylic acid, Outline of health sciences, Vitamin D, Blood, Sustainability, Health, WINCHESTER, Biochemistry, PLOS, Vitamin, PLOS ONE, Overweight, Cat, Human, Greenhouse, Environment, Dog, Immunity, Dietary supplement

WINCHESTER, ENGLAND, Apr 24, 2024 - (ACN Newswire) - The longest, most comprehensive peer-reviewed study so far has demonstrated that dogs fed nutritionally-sound vegan diets maintain health outcomes as well as dogs fed meat.

Key Points: 
  • WINCHESTER, ENGLAND, Apr 24, 2024 - (ACN Newswire) - The longest, most comprehensive peer-reviewed study so far has demonstrated that dogs fed nutritionally-sound vegan diets maintain health outcomes as well as dogs fed meat.
  • The study was particularly interesting, given recent suggestions that peas might contribute to heart disease in dogs in the US.
  • In the current study, dogs were fed pea-based vegan pet food, for one year.
  • Our study offers new evidence on outcomes in clinically healthy dogs who thrive without consumption of animal-derived ingredients.

Psilocybin Clinical Trial Sponsored by Clairvoyant Therapeutics Reaches 90% Randomization

Retrieved on: 
onsdag, april 3, 2024
Randomized controlled trial, Psilocybin, Safety, JAMA Psychiatry, Medicine, Marketing, Clinical trial, CMA

Clairvoyant's randomized controlled trial, CLA-PSY-201, has dosed more than 90 per cent of the expected 128 subjects for its 24-week Phase 2b clinical trial of synthetic psilocybin treatment for AUD (two dosing sessions of a 25 mg oral capsule over 8 weeks) at 12 active clinical sites in Canada and Europe.

Key Points: 
  • Clairvoyant's randomized controlled trial, CLA-PSY-201, has dosed more than 90 per cent of the expected 128 subjects for its 24-week Phase 2b clinical trial of synthetic psilocybin treatment for AUD (two dosing sessions of a 25 mg oral capsule over 8 weeks) at 12 active clinical sites in Canada and Europe.
  • A top line read out from the clinical trial is expected in Q3 2024 and a Series A financing round is currently underway.
  • "We are quickly approaching a critical and exciting moment for psilocybin and its potential use as a recognized treatment," said Damian Kettlewell, CEO, Clairvoyant.
  • Clairvoyant intends to launch a pivotal confirmatory trial in H2 2025, with a read out in 2027, to support full approval of psilocybin treatment in Canada, the EU and UK.

Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results

Retrieved on: 
torsdag, maj 9, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Clinical Trials, FDA, COYA, University, FTD, Society, Cancer, Viral, Laboratory, Survival, Coya, Conference, GM-CSF, Nebraska Medicine, IND, Granulocyte-macrophage colony-stimulating factor, Pharmacology, Frontotemporal dementia, Patient, Caregiver, Medulla oblongata, Serum, ALS, Diagnosis, PD, Therapy, Pharmaceutical industry

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended March 31, 2024.

Key Points: 
  • Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended March 31, 2024.
  • Additionally, clinical data from the previously completed investigator-initiated trial in patients with ALS is also anticipated in the second quarter.
  • 2 investigator-initiated trial involving COYA 301, or low-dose IL-2 alone, is expected in the summer of 2024.
  • As of March 31, 2024, Coya had cash and cash equivalents of $36.0 million.

OmniAb Reports First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
torsdag, maj 9, 2024
Health, Stem Cells, Research, Pharmaceutical, Science, Biotechnology, Investment, Teclistamab, Partnership, Myasthenia gravis, Trial of the century, Growth, Hook effect, ASCO, Journal, Lung cancer, Graves' ophthalmopathy, Pharmacokinetics, National Medical Products Administration, Conference, Fluorouracil, Patent, Telephone, NSCLC, Merck Group, Safety, Pembrolizumab, Artificial intelligence, CEACAM5, Autoimmune disease, Immunology, Monoclonal antibody, Clinical trial, University, TED, Sale, Chicken, Bystander effect, Antigen, Neonatal Fc receptor, Patient, Society, Pharmaceutical industry

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates.
  • “The OmniAb team continued to make great progress this past quarter in advancing and expanding our portfolio and partnership base.
  • General and administrative expense was $8.3 million for the first quarter of 2024, compared with $8.2 million for the same period in 2023.
  • As of March 31, 2024, OmniAb had cash, cash equivalents and short-term investments of $69.0 million.

Xencor Reports First Quarter 2024 Financial Results

Retrieved on: 
torsdag, maj 9, 2024
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, FDA, CD3, Cancer, Bangladesh Technical Education Board, CLDN6, Investment, Cell, NIH, Xtend, Malaria, NMOSD, Research, IND, Prostate cancer, European, CD28, Ravulizumab, Patient, ENPP3, Alexion, Immune system, Clinical trial, Ovarian cancer

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a review of recent clinical and business highlights.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a review of recent clinical and business highlights.
  • New Chief Financial Officer Appointed: Bart Cornelissen was appointed as Xencor’s senior vice president and chief financial officer.
  • Financial Results for the First Quarter Ended March 31, 2024
    Cash, cash equivalents and marketable debt securities totaled $646.7 million as of March 31, 2024, compared to $697.4 million on December 31, 2023.
  • Revenues for the first quarter ended March 31, 2024 were $12.8 million, compared to $19.0 million for the same period in 2023.

Curaleaf Reports First Quarter 2024 Results

Retrieved on: 
torsdag, maj 9, 2024
Pillar, Table, NGC, Net, News, THC, Depreciation, TSX, Public expenditure, Automation, Cannabis, Tax, Senior, Acquisition, MCO, Purchasing, MSO, GAAP, Growth, Earnout, Security (finance)

NEW YORK, May 9, 2024 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, today reported its financial and operating results for the first quarter ended March 31, 2024. All financial information is reported in accordance with U.S. generally accepted accounting principles (GAAP) and is provided in U.S. dollars unless otherwise indicated.

Key Points: 
  • First quarter 2024 revenue of $339 million, representing an increase of 2% year-over-year and adjusted gross margin(1) of 48%
    First quarter 2024 adjusted EBITDA(1) of $77 million, representing 23% of revenue, a 40 basis point improvement year-over-year
    NEW YORK, May 9, 2024 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, today reported its financial and operating results for the first quarter ended March 31, 2024.
  • Boris Jordan, Executive Chairman of Curaleaf, stated, "Consistent with our expectations, first quarter revenue grew 2% to $339 million, and we achieved a 48% adjusted gross margin.
  • Curaleaf International rebranded Sapphire Clinics to Curaleaf Clinics in the U.K.
    Acquired Can4Med, an experienced pharmaceutical wholesaler in Poland to enhance our market presence.
  • Curaleaf reports its financial results in accordance with GAAP and uses a number of financial measures and ratios when assessing its results and measuring overall performance.

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on: 
torsdag, maj 9, 2024
FDA, United Nations, Daiichi Sankyo, Blood, Pancreatic cancer, SOC, European Commission, News, TCE, Doctor of Philosophy, ONC, PDAC, CADL, Usenet newsgroup, Pancreatic Cancer Action Network, AstraZeneca, Anal cancer, Congress, United States Congress, TSX, Tumor microenvironment, Therapy, TME, Safety, Survival, TILS, Research, Cancer, Ethics, Mantle cell lymphoma, Chemoradiotherapy, Pharma, Progression-free survival, Immunotherapy, MD, United, Patient, Caregiver, Standard of care, Pharmaceutical industry

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points: 
  • The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
  • "We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
  • Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
  • Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on: 
torsdag, maj 9, 2024
FDA, United Nations, Daiichi Sankyo, Blood, Pancreatic cancer, SOC, European Commission, News, TCE, Doctor of Philosophy, ONC, PDAC, CADL, Usenet newsgroup, Pancreatic Cancer Action Network, AstraZeneca, Anal cancer, Congress, United States Congress, TSX, Tumor microenvironment, Therapy, TME, Safety, Survival, TILS, Research, Cancer, Ethics, Mantle cell lymphoma, Chemoradiotherapy, Pharma, Progression-free survival, Immunotherapy, MD, United, Patient, Caregiver, Standard of care, Pharmaceutical industry

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points: 
  • The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
  • "We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
  • Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
  • Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on: 
torsdag, maj 9, 2024
FDA, United Nations, Daiichi Sankyo, Blood, Pancreatic cancer, SOC, European Commission, TCE, Doctor of Philosophy, ONC, PDAC, CADL, Pancreatic Cancer Action Network, AstraZeneca, Anal cancer, Congress, News, United States Congress, TSX, Tumor microenvironment, Therapy, TME, Safety, Survival, TILS, Research, Cancer, Ethics, Mantle cell lymphoma, Chemoradiotherapy, Pharma, Progression-free survival, Immunotherapy, MD, United, Patient, Caregiver, Standard of care, Pharmaceutical industry

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points: 
  • The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
  • "We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
  • Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
  • Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on: 
torsdag, maj 9, 2024
FDA, United Nations, Daiichi Sankyo, Blood, Pancreatic cancer, SOC, European Commission, TCE, Doctor of Philosophy, ONC, PDAC, CADL, Pancreatic Cancer Action Network, AstraZeneca, Anal cancer, Congress, News, United States Congress, TSX, Tumor microenvironment, Therapy, TME, Safety, Survival, TILS, Research, Cancer, Ethics, Mantle cell lymphoma, Chemoradiotherapy, Pharma, Progression-free survival, Immunotherapy, MD, United, Patient, Caregiver, Standard of care, Pharmaceutical industry

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points: 
  • The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
  • "We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
  • Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
  • Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.